摘要
目的:检测白血病患者血清环氧合酶-2(COX-2)表达水平,探索其临床意义。方法:采用酶联免疫吸附法(ELISA)对白血病患者、良性血液病患者及正常健康对照组血清COX-2表达水平进行检测,比较3组之间有无差异,以及治疗前后对比。结果:72例初诊患者的血清COX-2水平(17.62±10.18)ng/L,明显高于正常对照组和良性血液病组(均P<0.01)。治疗有效者COX-2水平(12.42±4.89)ng/L,与治疗前比较差异有统计学意义。结论:COX-2与白血病发生、发展密切相关,它对白血病治疗、病情监测及预后判断等具有指导意义。
Objective：To determine the serumal cyclooxygenase-2 level in leukemia patients and assess the clinical significance. Method：Serum COX-2 levels in of patients with leukemia, non-malignant hematonosis and healthy control were determined by enzyme linked-immunosorbent assay （ELISA）. Result： Serum cyclooxygenase-2 levels in 72 cases of newly diagnosed leukemia patients were （17.62 ± 10.18） pg/ml, which was obviously higher than that of control （ P 〈0.01）. In 45 cases of leukemia patients with complete remission （CR） or partly remission （PR）, the serum eyclooxygenase-2 levels were （12.42 ± 4.89） pg/ml, which was obviously lower than that of pretherapy. Conclusion：COX-2 is closely related to the genesis and progress （growth） of leukemia. It plays an important role in treatment, monitoring and prognosis of leukemia.
出处
《临床血液学杂志》
CAS
2009年第2期135-136,140,共3页
Journal of Clinical Hematology
